Company ·
Hanmi Pharmaceutical holds a peptide molecule tracked on the Peptide Exchange board.
Hanmi Pharmaceutical has 1 molecule on the board and 2 news moves logged. Each card shows the molecule's class, mechanism and current stage; open it for the full stage history.
Holdings
Incretins
Long acting GLP-1 receptor agonist
Hanmi's weekly GLP-1 agonist, once licensed to Sanofi for diabetes and returned in 2020. Approved in South Korea for weight management in October 2026 on a 448 person domestic phase 3.
Log
Hanmi's weekly GLP-1 injection reached Korean hospitals on 29 October with a first month priced below Mounjaro and Wegovy. Trial weight loss trails the leaders, supply is limited, and insurance decisions could narrow the gap.
Holds APP
South Korea's regulator cleared Hanmi's weekly efpeglenatide injection for chronic weight management after a 448 person domestic phase 3. Weight loss trails the market leaders; Hanmi is betting on tolerability and local supply.
FIL → APP